PE20090433A1 - Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion - Google Patents

Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Info

Publication number
PE20090433A1
PE20090433A1 PE2009000199A PE2009000199A PE20090433A1 PE 20090433 A1 PE20090433 A1 PE 20090433A1 PE 2009000199 A PE2009000199 A PE 2009000199A PE 2009000199 A PE2009000199 A PE 2009000199A PE 20090433 A1 PE20090433 A1 PE 20090433A1
Authority
PE
Peru
Prior art keywords
staurosporin
benzoyl
procedure
preparation
solution
Prior art date
Application number
PE2009000199A
Other languages
English (en)
Spanish (es)
Inventor
Pascale Hoehn
Bernd Koch
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090433(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20090433A1 publication Critical patent/PE20090433A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
PE2009000199A 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion PE20090433A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07

Publications (1)

Publication Number Publication Date
PE20090433A1 true PE20090433A1 (es) 2009-05-05

Family

ID=35501294

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2009000199A PE20090433A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2012002519A PE20130377A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2005001297A PE20060947A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2012002519A PE20130377A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2005001297A PE20060947A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Country Status (31)

Country Link
US (2) US8198435B2 (cg-RX-API-DMAC10.html)
EP (3) EP2955186A1 (cg-RX-API-DMAC10.html)
JP (4) JP5057986B2 (cg-RX-API-DMAC10.html)
KR (3) KR101265850B1 (cg-RX-API-DMAC10.html)
CN (2) CN102627658A (cg-RX-API-DMAC10.html)
AR (1) AR052322A1 (cg-RX-API-DMAC10.html)
AU (2) AU2005300693B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0517689A (cg-RX-API-DMAC10.html)
CA (1) CA2584911C (cg-RX-API-DMAC10.html)
CY (1) CY1113059T1 (cg-RX-API-DMAC10.html)
DK (1) DK1812448T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP12007431A (cg-RX-API-DMAC10.html)
ES (1) ES2388142T3 (cg-RX-API-DMAC10.html)
GT (1) GT200500311A (cg-RX-API-DMAC10.html)
HK (1) HK1211587A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20120652T1 (cg-RX-API-DMAC10.html)
IL (3) IL182691A (cg-RX-API-DMAC10.html)
JO (1) JO2897B1 (cg-RX-API-DMAC10.html)
MA (1) MA29033B1 (cg-RX-API-DMAC10.html)
MX (2) MX346525B (cg-RX-API-DMAC10.html)
MY (2) MY147404A (cg-RX-API-DMAC10.html)
NO (2) NO338960B1 (cg-RX-API-DMAC10.html)
NZ (3) NZ599033A (cg-RX-API-DMAC10.html)
PE (3) PE20090433A1 (cg-RX-API-DMAC10.html)
PL (1) PL1812448T3 (cg-RX-API-DMAC10.html)
PT (1) PT1812448E (cg-RX-API-DMAC10.html)
RU (2) RU2394038C2 (cg-RX-API-DMAC10.html)
SI (1) SI1812448T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN07165A1 (cg-RX-API-DMAC10.html)
TW (4) TWI530501B (cg-RX-API-DMAC10.html)
WO (1) WO2006048296A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
US20200010481A1 (en) 2017-03-06 2020-01-09 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
WO2020261293A1 (en) * 2019-06-24 2020-12-30 Dr. Reddy's Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5073633A (en) 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
EP0575955B1 (en) 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
US6878804B1 (en) * 1999-08-30 2005-04-12 University Of Zurich Synthesis of template-fixed β-hairpin loop mimetics
WO2002076432A2 (en) 2001-03-26 2002-10-03 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US7608420B2 (en) * 2003-04-22 2009-10-27 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
JP2012149099A (ja) 2012-08-09
CA2584911C (en) 2017-10-24
IL217571A (en) 2017-07-31
JO2897B1 (en) 2015-09-15
AU2009245817B2 (en) 2013-02-21
HK1108881A1 (en) 2008-05-23
CN102627658A (zh) 2012-08-08
KR20120101600A (ko) 2012-09-13
MA29033B1 (fr) 2007-11-01
BRPI0517689A (pt) 2008-10-14
AU2005300693A1 (en) 2006-05-11
NZ599033A (en) 2012-09-28
US20090137552A1 (en) 2009-05-28
JP2017061578A (ja) 2017-03-30
IL182691A0 (en) 2007-09-20
CA2584911A1 (en) 2006-05-11
NO338960B1 (no) 2016-11-07
SI1812448T1 (sl) 2012-09-28
TWI433852B (zh) 2014-04-11
KR101265850B1 (ko) 2013-05-20
KR20070083979A (ko) 2007-08-24
HK1211587A1 (en) 2016-05-27
KR20120101601A (ko) 2012-09-13
TWI455941B (zh) 2014-10-11
MY147404A (en) 2012-11-30
DK1812448T3 (da) 2012-08-27
JP5701246B2 (ja) 2015-04-15
TWI530500B (zh) 2016-04-21
EP2272850A2 (en) 2011-01-12
GT200500311A (es) 2006-05-22
NO20161152A1 (no) 2007-05-30
JP2008518995A (ja) 2008-06-05
NZ588025A (en) 2012-04-27
AU2009245817A1 (en) 2009-12-24
ECSP12007431A (es) 2012-06-29
PL1812448T3 (pl) 2012-10-31
NZ554653A (en) 2010-10-29
RU2467012C2 (ru) 2012-11-20
TNSN07165A1 (en) 2008-11-21
NO340404B1 (no) 2017-04-18
CY1113059T1 (el) 2016-04-13
RU2007120695A (ru) 2008-12-10
EP2955186A1 (en) 2015-12-16
TW201446773A (zh) 2014-12-16
MX2007005429A (es) 2007-05-18
TWI530501B (zh) 2016-04-21
EP2272850A3 (en) 2011-09-21
TW200628474A (en) 2006-08-16
HRP20120652T1 (hr) 2012-09-30
JP2015063569A (ja) 2015-04-09
WO2006048296A1 (en) 2006-05-11
PT1812448E (pt) 2012-08-24
PE20060947A1 (es) 2006-10-30
MX346525B (es) 2017-03-23
EP1812448B1 (en) 2012-05-23
US20120322789A1 (en) 2012-12-20
JP5057986B2 (ja) 2012-10-24
RU2394038C2 (ru) 2010-07-10
US8710216B2 (en) 2014-04-29
CN102993213A (zh) 2013-03-27
IL182691A (en) 2013-02-28
RU2009137788A (ru) 2011-04-20
TW201247680A (en) 2012-12-01
AU2005300693B2 (en) 2010-08-19
PE20130377A1 (es) 2013-04-03
EP2272850B1 (en) 2017-05-10
IL207702A0 (en) 2010-12-30
US8198435B2 (en) 2012-06-12
KR101289998B1 (ko) 2013-07-30
TW201247681A (en) 2012-12-01
ES2388142T3 (es) 2012-10-09
EP1812448A1 (en) 2007-08-01
NO20072290L (no) 2007-05-30
IL207702A (en) 2016-09-29
KR101333851B1 (ko) 2013-11-27
AR052322A1 (es) 2007-03-14
MY154878A (en) 2015-08-14

Similar Documents

Publication Publication Date Title
AR062148A1 (es) Proceso quimico para la preparacion de intermediarios
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
NO20081101L (no) Regioselektiv metode for fremstilling av benzimidazol-tiofener
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
WO2010067374A3 (en) Polymorphs of dasatinib
ECSP055910A (es) Nuevos acidos carboxilicos y sus esteres, medicamentos que contienen estos compuestos y procedimientos para su preparacion
CL2012000560A1 (es) Procedimiento de preparacion del compuesto intermediario acido 3-oxo-tetrahidrotiofeno-2-carboxilico, utiles en la preparacion de dihidrotienopirimidinas (divisional de la solicitud 3095-08).
WO2012031045A3 (en) Phosphonate ester derivatives and methods of synthesis thereof
UY31460A1 (es) Procedimiento de preparacion de compuestos morfinicos
EP2407444A3 (en) Process for the preparation of dodecanedioic acid
CL2009001414A1 (es) Procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-benzazepin-2-ona sin aislacion de compuestos intermediarios; util para la sintesis de ivabradina.
AR078916A1 (es) Procedimiento para la purificacion de paliperidona
AR051341A1 (es) Proceso para la preparacion de derivados de [1,4,5]-oxadiazepina
ATE294183T1 (de) Verbesserte herstellung von ceftiofur zwischenprodkten
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
ATE485261T1 (de) Salicylsäurederivate
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
WO2009116072A3 (en) Process for preparation of pyridinylmethylsulphinyl benzimidazole compounds and pyridine intermediates
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
WO2010064785A3 (en) Method for selectively crystallizing a z isomer of iopromide
NZ598278A (en) Process for preparing biphenyl imidazole compounds
PL2010538T3 (pl) Sposób otrzymywania estru 2-[4-(4-fluoro-2-metylo-1H-indolo-5-iloksy)-5-metylopirolo[2,1-f][1,2,4]triazyn-6-iloksy]-1-metyloetylowego kwasu [(1R), 2S]-2-aminopropionowego
PE20090534A1 (es) Polimorfos de s,s-dioxido del acido 7-[(3-cloro-6,11-dihidro-6-metildibenzo[c,f] [1,2]tiazepin-11-il)amino]heptanoico y metodos para su preparacion y uso
SG162815A1 (en) Process for preparing benzimidazole compounds

Legal Events

Date Code Title Description
FC Refusal